[HTML][HTML] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
…, L Fehrenbacher, MJ Moore, JA Maroun… - … England Journal of …, 2000 - Mass Medical Soc
Background The combination of fluorouracil and leucovorin has until recently been standard
therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with …
therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with …
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.
…, KI Pritchard, WK Evans, JA Maroun… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE To present an update on the development of oncology practice guidelines (PGs)
using the Practice Guidelines Development Cycle (Cycle), and to present the results of …
using the Practice Guidelines Development Cycle (Cycle), and to present the results of …
Pharmacokinetics and clinical efficacy of oral morphine solution and controlled‐release morphine tablets in cancer patients
MP Thirlwell, PA Sloan, JA Maroun, GJ Boos… - Cancer, 1989 - Wiley Online Library
Twenty‐three adult patients with chronic pain due to cancer completed a double‐blind,
randomized, two‐phase crossover trial comparing plasma morphine concentrations and …
randomized, two‐phase crossover trial comparing plasma morphine concentrations and …
A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram
S Verma, DJ Stewart, JA Maroun… - American journal of …, 1990 - journals.lww.com
Preclinical evidence has suggested that disulfiram (DS) and related compounds can decrease
the toxicity and enhance the therapeutic index of cisplatin (CP). To study this further, we …
the toxicity and enhance the therapeutic index of cisplatin (CP). To study this further, we …
Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection
…, B Le François, JA Maroun… - Anticancer …, 2008 - ar.iiarjournals.org
Background: 5-Fluorouracil (5-FU) is an antineoplastic drug that targets thymidylate synthase
(TS). Tumour cells can develop resistance to anti-TS drugs by a variety of mechanisms …
(TS). Tumour cells can develop resistance to anti-TS drugs by a variety of mechanisms …
Platinum concentrations in human autopsy tumor samples
…, V Montpetit, A Nanji, JA Maroun… - American journal of …, 1988 - journals.lww.com
Platinum concentrations were determined in autopsy tumor samples obtained from 27
patients who had received cisplatin 40–1,029 mg/m 2 from 0 to 240 days antemortem. Liver …
patients who had received cisplatin 40–1,029 mg/m 2 from 0 to 240 days antemortem. Liver …
Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose …
WK Hong, C Nicaise, R Lawson, JA Maroun… - Journal of Clinical …, 1989 - ascopubs.org
A total of 353 patients with previously untreated small-cell lung cancer (SCLC) were accrued
in this multicenter trial. Patients were randomly assigned to receive one of the following …
in this multicenter trial. Patients were randomly assigned to receive one of the following …
AmpFℓSTR® Profiler Plus™ and AmpFℓSTR® COfiler™ Analysis of Tissues Stored in GenoFix™, a New Tissue Preservation Solution for Mass Disaster DNA …
…, S Borys, D McLean, JA Maroun… - Journal of …, 2001 - asmedigitalcollection.asme.org
A preliminary study was conducted to assess the capability of a new alcohol-based tissue
fixative, GenoFix™, to preserve DNA from biopsy tissues stored at room temperature and/or -20…
fixative, GenoFix™, to preserve DNA from biopsy tissues stored at room temperature and/or -20…
Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study …
HJ Schmoll, J Tabernero, JA Maroun… - Journal of Clinical …, 2012 - ascopubs.org
388 Background: The MOSAIC trial demonstrated that adding oxaliplatin to 5-FU/LV (FOLFOX4)
improved 3-year disease-free survival (DFS) compared to infusional and bolus 5-FU/LV …
improved 3-year disease-free survival (DFS) compared to infusional and bolus 5-FU/LV …
Phase I study of the combination of disulfiram with cisplatin
DJ Stewart, S Verma, JA Maroun - American journal of clinical …, 1987 - journals.lww.com
In light of preclinical evidence that disulfiram and related compounds decrease the toxicity
and increase the therapeutic index of cisplatin, 12 patients were treated with a combination of …
and increase the therapeutic index of cisplatin, 12 patients were treated with a combination of …